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Abstract
Introduction—Gemcitabine is an important component of pancreatic cancer clinical 
management. Unfortunately, acquired gemcitabine resistance is widespread and there are 
limitations to predicting and monitoring therapeutic outcomes.
Objective—To investigate the potential of metabolomics to differentiate pancreatic cancer cells 
that develops resistance or respond to gemcitabine treatment.
Results—We applied 1D 1H and 2D 1H-13C HSQC NMR methods to profile the metabolic 
signature of pancreatic cancer cells. 13C6-glucose labeling identified thirty key metabolites 
uniquely altered between wild-type and gemcitabine-resistant cells upon gemcitabine treatment. 
Gemcitabine resistance was observed to reprogram glucose metabolism and to enhance the 
pyrimidine synthesis pathway. Myo-inositol, taurine, glycerophosphocholine and creatinine 
phosphate exhibited a “binary switch” in response to gemcitabine treatment and acquired 
resistance.
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Conclusion—Metabolic differences between naïve and resistant pancreatic cancer cells and, 
accordingly, their unique responses to gemcitabine treatment were revealed, which may be useful 
in the clinical setting for monitoring a patient’s therapeutic response.
Keywords
NMR metabolomics; pancreatic cancer; gemcitabine; drug resistance
Introduction
A drug has to pass through a variety of complex biological systems and must survive 
different cellular processes in order to reach its molecular target and exhibit a positive 
therapeutic response. In many instances, both the drug and the exposed cells undergo 
molecular change that either favors the desired outcome or leads to the development of 
resistance. Acquired resistance has been well-documented in the application of antibiotics 
and is commonly due to the overexposure or incorrect administration of the drugs. In this 
regard, bacteria rapidly acquire antibiotic resistance by altering their genetic expression, 
protein structure or metabolic processes. Since antimicrobial resistance is such a common 
problem, an array of therapeutic approaches and improved sensitivity tests have been 
developed to monitor a patient’s response to treatment and to improve therapeutic outcomes 
(Davies and Davies 2010; Housman et al. 2014). Similar efforts are on-going to combat 
acquired resistance for anticancer therapeutics. This has led to increased efforts to 
understand mechanisms of drug resistance and for the development of methods to test 
patient-specific drug sensitivity (Uhr et al. 2015). However, there are still serious unmet 
needs to achieving precision cancer therapies by identifying an optimal cancer-cell specific 
treatment (Bardin et al. 2014).
Cancer cells employ a variety of mechanisms to acquire resistance against 
chemotherapeutics (Rahman and Hasan 2015). In which, metabolic rewiring of tumors has 
been identified as a critical step in drug resistance. Cancer cells alter their metabolism by 
monitoring nutrient uptake (such as glucose and glutamine), which results in modulating 
certain metabolic pathways in response. Gemcitabine is an antimetabolite drug widely used 
in the treatment of breast, lung and pancreatic cancers. It is a prodrug activated by the effect 
of kinases in the cytoplasm. Gemcitabine is the first treatment of choice for pancreatic 
cancer patients, and is commonly used by its self or in combination therapies. Unfortunately, 
it is routine for patients to develop gemcitabine resistance shortly after beginning treatment 
(Fryer et al. 2011). We recently demonstrated that acquired resistance to gemcitabine results 
in the reprograming of glucose metabolism and an enhanced carbon-flow through the 
pyrimidine synthesis pathway (Shukla et al. 2017). This metabolic phenotype for pancreatic 
cancer cell lines is regulated by MUC1 and HIF1α cross-talk.
1D 1H NMR metabolomics is a versatile tool of systems biology that is routinely used to 
elucidate various metabolic alterations (Gebregiworgis and Powers 2012). Accordingly, we 
have utilized NMR metabolomics to study the impact of MUC1 overexpression (Chaika et 
al. 2012), to monitor tumor microenvironment alteration (Gebregiworgis et al. 2017), and as 
a means to reverse antibiotic resistance (Gaupp et al. 2015; Gardner et al. 2018). NMR 
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metabolomics provides a detailed and specific analysis of metabolic perturbations by 
combining stable isotope labeling schemes (e.g., 13C glucose) with two dimensional (2D) 
NMR experiments (e.g., 1H-13C HSQC, HMBC, etc.). In this communication, we extend our 
investigation into the altered metabolism of gemcitabine resistance cell lines; and describe a 
global metabolic response to gemcitabine treatment.
Results and Discussion
Unique metabolic phenotype for gemcitabine resistant cells.
Briefly, ten replicates for each of the wild-type (WT, human pancreatic cancer cell line: 
T3M4 or Capan-1), gemcitabine resistant (GemR), WT treated with 10 nM of gemcitabine 
(WT+), and GemR treated with 10 nM of gemcitabine (GemR+) cell cultures were prepared 
as previously described for the 1D 1H NMR experiments (Shukla et al. 2017). As previously 
reported, the 10 nM gemcitabine dosage is significantly below a dosage (~1 μM) required to 
induce cell death in any of the cell lines (Shukla et al. 2017). Similarly, three additional 
replicates of WT, GemR, WT+, and GemR+ Capan-1 cells were prepared where the glucose 
in the culture media was replaced with 0.5 mM of 13C6-glucose. Please see the supplemental 
material for additional experimental details.
The 1D 1H NMR spectra collected from each cell lysate was analyzed using our MVAPACK 
metabolic toolkit (http://bionmr.unl.edu/mvapack.php) to generate a principal component 
analysis (PCA) model (Worley and Powers 2014). An unsupervised PCA model was used to 
illustrate the unique metabolic signature for each cell type, and to identify metabolic 
alterations that resulted from either gemcitabine resistance or from gemcitabine treatment 
(Gebregiworgis and Powers 2012). The resulting PCA scores plots and associated tree 
diagrams shown in Figures 1A, B and Figure S-1 clearly indicates that the metabolomes 
from the WT and WT-treated cells form distinct and separate groups. Conversely, the 
metabolomes from GemR and GemR-treated cells clustered together but separately from the 
gemcitabine-sensitive metabolomes.
The PCA scores plot demonstrates the overall metabolic impact of gemcitabine treatment on 
sensitive cells; and the corresponding lack of a response for resistant cells. Furthermore, the 
PCA scores plot identifies the presence of a metabolic adaptation for gemcitabine resistant 
cells. In effect, a distinct metabolic phenotype was observed for pancreatic cancer cells 
resistant to gemcitabine treatment. Furthermore, the observed alteration in metabolism may 
facilitate our understanding of the mechanism of gemcitabine resistance and provide a 
means to reverse the process (de Sousa Cavalcante and Monteiro 2014). Importantly, our 
results demonstrate a potential utility in precision medicine since the distinct metabolic 
phenotypes observed for WT and GemR cell lines may be leveraged for predicting a 
patient’s response to a gemcitabine treatment.
An orthogonal projection to latent structures - discriminant analysis (OPLS-DA) model was 
also generated from the 1D 1H NMR datasets to identify key metabolites that contribute to 
group specific separations (Figure S-2). Accordingly, the OPLS-DA model comparing the 
WT and WT-treated metabolome identified key-metabolic changes in response to 
gemcitabine treatment. The high-quality and statistical validity of the resulting OPLS-DA 
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model from the WT/WT+ NMR dataset is evident by an R2 of 0.99, a Q2 of 0.90, a CV-
ANOVA p-value of 7.9 × 10−7, and a permutation test p-value of 0. A back-scaled loadings 
plot generated from the OPLS-DA model is shown in Figure 1C. A total of sixteen 
metabolite changes were identified from the back-scaled loadings plot that significantly 
contributes to the metabolome differences between WT and WT-treated cells. The key 
metabolite changes between WT and WT+ are summarized in the pathway diagram shown 
in Figure 1D. An OPLS-DA model was similarly generated from the WT/GemR NMR 
dataset to identify key metabolite changes associated with gemcitabine resistance. The high-
quality and statistical validity of the resulting OPLS-DA model from the WT/GemR NMR 
dataset is evident by an R2 of 0.99, a Q2 of 0.96, a CV-ANOVA p-value of 2.52 × 10−7, and 
a permutation test p-value of 0. Notably, the same set of sixteen metabolites w identified 
from the WT/GemR OPLS-DA back-scaled loadings plot as was observed in the WT/WT+ 
OLPS-DA model (Figures 1E, F). But, significantly, the relative metabolite trends are 
reversed when these two statistical models are compared. Specifically, acetate, alanine, and 
glutathione are increased in GemR cells compared to WT, while glycine, myo-inositol, 
taurine, glycerophospocholine, and creatinine phosphate are decreased in GemR cells 
relative to WT (Figure 1D and 1F). Again, these metabolic trends are completely reversed 
when WT-treated cells are compared to WT cells. Importantly, the metabolites involved in 
this metabolic “switch” have been previously linked to pancreatic cancer.
Myo-inositol and its metabolites regulate cancer cell proliferation, migration and the 
phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway (Vucenik and Shamsuddin 
2003). Accordingly, many genes and pathways associated with myo-inositol synthesis and 
its biological activity have also been correlated with pancreatic cancer. Interestingly, natural 
and synthetic derivatives of myo-inositol have a demonstrated anticancer activity by 
reducing HIF1α expression and by decreasing the cellular concentration of nucleotides. 
Furthermore, the myo-inositol induced reduction in nucleotide concentrations also enhances 
gemcitabine efficacy (Raykov et al. 2014). Thus, drugs that target myo-inositol metabolism 
may also reverse gemcitabine resistance, and may be useful as part of a combination therapy.
Serine derived glycine is a precursor of single carbon metabolism and de novo purine 
nucleotide synthesis, which are critical processes in cancer pathogenesis (Yang and Vousden 
2016). As noted above, a reduction in the cellular concentration of nucleotides enhances 
gemcitabine efficacy. Alternatively, an increase in glycine uptake and its metabolism has 
been observed to promote tumorigenesis (Amelio et al. 2014). Glycine is also an important 
metabolite in glutathione biosynthesis (Lu 2009). An increase in the expression of 
glutathione generating enzymes has been previously associated with gemcitabine resistance 
(Ju et al. 2015). Gemcitabine is known to increase reactive oxygen species and, presumably, 
an increase in the production of glutathione would negate the impact of this additional ROS. 
Consistent with these prior observations, we observed a decrease in glycine and a concurrent 
increase in glutathione in GemR. This could be attributed to an increase in the 
transformation of glycine into glutathione to combat gemcitabine-induced ROS. The 
reduction in glycine may also be a result of an increase of carbon-flow into nucleotide 
synthesis.
Gebregiworgis et al. Page 4





















Alanine metabolism is a critical source of stromal cell derived fuel for cancer cell 
proliferation and survivability (Sousa et al. 2016). Thus, alterations in alanine metabolism 
may be an important process for acquiring gemcitabine resistance. Our observation that 
alanine metabolism was altered in both GemR and WT-treated cells are consistent with this 
viewpoint. Specifically, we observed a decrease in alanine in WT-treated cells and a 
corresponding increase in GemR cells. This result is also consistent with the observation that 
elevated alanine transaminase serum levels is linked to a poor therapeutic outcome and the 
development of gemcitabine resistance (Matsubara et al. 2010).
Acetate is a major carbon source for fatty acid and phospholipid biosynthesis, particularly in 
proliferating cancer cells and during metabolic stress. Acetyl-CoA synthetase 2 (ACSS2) 
catalyzes the conversion of acetate to acetyl-CoA. ACSS2 has been observed to inhibit 
tumor growth when depleted in hepatocellular carcinoma xenografts (Comerford et al. 
2014). Our observation that acetate is depleted in WT-treated, but increased in GemR cells, 
highlights that acetate could serve as an important fuel for proliferating cancer cells.
Taurine has been previously observed to have an anti-proliferative effect on breast, colon, 
cervical, and hepatic cancers (Tu et al. 2015). In this regard, an increase in taurine 
concentration leads to apoptosis. Taurine was increased in the WT+ cells, but decreased in 
GemR. Our observations align with previous reports indicating that an acquired gemcitabine 
resistance inhibits gemcitabine-induced apoptosis.
A connection between creatine/creatine phosphate and pancreatic cancer has not been 
previously observed. Nevertheless, an alteration in the expression of creatine kinase, the 
enzyme that catalyzes the reversible conversion of creatine to creatine phosphate, has been 
strongly associated with other tumors such as small cell lung carcinoma (Gazdar et al. 
1981).
A notable decrease in glycerophosphocholine was also observed in GemR cells with a 
corresponding increase in WT+ cells. This is consistent with abnormal choline metabolism 
that is a characteristic of multiple cancers and the associated changes in the expression of 
important choline metabolizing enzymes and choline transporters (Glunde et al. 2015). Since 
11C Choline PET imaging is already used for diagnosing cancer (Hara et al. 1998), choline 
metabolism might yield a promising biomarker for gemcitabine-sensitive pancreatic cancers.
A receiver operating characteristics (ROC) analyses was applied to further asses the 
predictive power of the NMR metabolomics data to discriminate WT (T3M4 and Capan-1) 
cells from WT+ and GemR cells. The ROC curves (Figure S-3) show that the WT, WT+ and 
GemR cells were all confidently identified (AUC > 0.9) using only five spectral features 
from the 1D 1H NMR data sets. Notably, each of these spectral features was similarly 
identified from the OPLS-DA loadings plots. Thus, the essentially identical results obtain 
from both univariate and multivariate analysis for two different cell lines provides strong 
validation for the observed alteration in the cellular metabolomes.
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Altered metabolism in gemcitabine resistant cells.
We have previously demonstrated that glucose metabolism is altered in gemcitabine resistant 
cells (Shukla et al. 2017). The application of stable isotope-resolved metabolomics (SIRM) 
techniques provides further confirmation for the role of metabolism in gemcitabine 
resistance. 2D 1H-13C heteronuclear single quantum coherence (HSQC) NMR spectra was 
used to analyze the metabolites derived from 13C6-glucose in WT Capan-1, WT-treated, 
GemR and GemR-treated cell lysates. A total of thirty metabolites were identified from the 
2D 1H-13C HSQC NMR spectra. The relative metabolite concentrations are plotted in a 
heatmap with hierarchical clustering (Figure 2A). Consistent with the PCA analysis of the 
1D 1H NMR dataset (Figures 1 and S-1), two major branches consisting of WT/WT+ and 
GemR/GemR+ was observed in the heatmap. Again, this indicates that a metabolic 
phenotype associated with gemcitabine-resistance was the major feature differentiating the 
four cell cultures. Furthermore, the gemcitabine sensitive cells formed two distinct branches 
based on gemcitabine treatment status. In contrast, the GemR cells formed a single branch 
irrespective of gemcitabine treatment.
In addition to clustering based on group membership, the metabolites in the heatmap were 
also hierarchically clustered (Figure 2A). As a result, the metabolites formed three distinct 
branches. The top branch contains metabolites that exhibited a decrease in concentration in 
response to acquiring gemcitabine resistance. This branch includes important metabolites 
such as glucose, glucose 6-phosphate, aspartate, and citric acids. The middle branch contains 
metabolites that all increased in concentration upon developing gemcitabine resistance. 
These metabolites include nucleotide analogs of adenine, cytidine, guanine and uracil along 
with amino acids such as glutamine, and alanine. The bottom cluster contains metabolites 
with distinct patterns dependent on the cell lines gemcitabine treatment. In effect, these 
metabolites primarily reflect the response of WT cells to treatment and are major 
contributors to distinguishing WT from WT+ cells.
The pathway shown in Figure 2B summarizes the metabolic changes that resulted from 
either gemcitabine resistance (first arrow) or from WT cell’s response to treatment (second 
arrow). The acquisition of gemcitabine resistance resulted in a major metabolic “switch”. 
This is further evident by the complete pairwise reversal in metabolite concentration changes 
as depicted in Figure 2B. Specifically, if a metabolite increased as a result of acquiring 
gemcitabine resistance, it was then observed to decrease in the WT cell’s response to 
gemcitabine treatment or vice-versa.
Our NMR metabolomics analysis indicated that GemR cells exhibited an altered nucleotide 
biosynthesis, which resulted from a redirection in carbon-flow from other major metabolic 
pathways. Specifically, metabolites from glycolysis and the pentose phosphate pathway were 
decreased in GemR. Presumably, this was a result of carbon flowing from glycolysis and 
PPP into nucleotide biosynthesis in order to increase the cellular concentration of 
nucleotides. This is consistent with prior observations that gemcitabine efficacy is affected 
by the nucleotide cellular pool (Raykov et al. 2014) and our observation that deoxycytidine 
triphosphate is a competitive-inhibitor of gemcitabine (Shukla et al. 2017). Again, the 
metabolic response of gemcitabine sensitive cells (e.g., wild-type cells) to a gemcitabine 
treatment was a complete reversal of the response in gemcitabine-resistant cells (e.g., 
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GemR). In summary, GemR cells and WT-treated cells metabolize glucose differently. In 
GemR, glucose is primarily funneled into nucleotide synthesis to negate gemcitabine 
activity; whereas, glucose is primarily directed into aerobic glycolysis in a WT cell’s 
response to gemcitabine treatment.
Conclusion
A unique metabolic phenotype was identified for pancreatic cancer cells with an acquired 
resistance to gemcitabine. A metabolic “switch” was observed when comparing 
gemcitabine-resistant cells to a wild-type cell’s response to gemcitabine treatment. This 
metabolic switch enabled gemcitabine-resistant cells to funnel carbon from glucose into 
nucleotide biosynthesis, where the increased cellular pool of nucleotides function as a 
competitive inhibitor of gemcitabine. The distinct metabolic profiles for both a response to 
treatment and an acquired-drug resistance suggest a potential utility of metabolomics for 
monitoring a patient’s response to gemcitabine therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported in part by funding from the National Institutes of Health grant (R01 CA163649, NCI) to 
P.K.S. and R.P.; the Redox Biology Center (P30 GM103335, NIGMS) to R.P.; the Nebraska Center for Integrated 
Biomolecular Communication (P20 GM113126, NIGMS) to R.P.; American Association for Cancer Research 
(AACR) -Pancreatic Cancer Action Network (PanCAN) Career Development Award (30-20-25-SING) to P.K.S.; 
the Specialized Programs for Research Excellence (SPORE, 2P50 CA127297, NCI) to P.K.S.; Pancreatic Tumor 
Microenvironment Research Network (U54, CA163120, NCI) to P.K.S.; and Fred & Pamela Buffett Cancer Center 
Support Grant (P30CA036727) to P.K.S. and R.P. The research was performed in facilities renovated with support 
from the National Institutes of Health (RR015468-01). The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
References
Amelio I, Cutruzzola F, Antonov A, Agostini M, & Melino G (2014). Serine and glycine metabolism 
in cancer. Trends Biochem Sci, 39(4), 191–198, doi:10.1016/j.tibs.2014.02.004. [PubMed: 
24657017] 
Bardin C, Veal G, Paci A, Chatelut E, Astier A, Leveque D, et al. (2014). Therapeutic drug monitoring 
in cancer--are we missing a trick? Eur J Cancer, 50(12), 2005–2009, doi:10.1016/j.ejca.
2014.04.013. [PubMed: 24878063] 
Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, et al. (2012). MUC1 
mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic 
cancer. Proc Natl Acad Sci U S A, 109(34), 13787–13792, doi:10.1073/pnas.1203339109. 
[PubMed: 22869720] 
Comerford Sarah A., Huang Z, Du X, Wang Y, Cai L, Witkiewicz Agnes K., et al. (2014). Acetate 
Dependence of Tumors. Cell, 159(7), 1591–1602, doi:10.1016/j.cell.2014.11.020. [PubMed: 
25525877] 
Davies J, & Davies D (2010). Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev, 
74(3), 417–433, doi:10.1128/mmbr.00016-10. [PubMed: 20805405] 
de Sousa Cavalcante L, & Monteiro G (2014). Gemcitabine: metabolism and molecular mechanisms of 
action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol, 741, 8–16, doi:
10.1016/j.ejphar.2014.07.041. [PubMed: 25084222] 
Gebregiworgis et al. Page 7





















Fryer RA, Barlett B, Galustian C, & Dalgleish AG (2011). Mechanisms underlying gemcitabine 
resistance in pancreatic cancer and sensitisation by the iMiD lenalidomide. Anticancer Res, 31(11), 
3747–3756. [PubMed: 22110196] 
Gardner SG, Somerville GA, Marshall DD, Powers R, Daum RS, Daum RS, et al. (2018). Metabolic 
Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility. Antimicrob 
Agents Chemother, 62(1).
Gaupp R, Lei S, Reed JM, Peisker H, Boyle-Vavra S, Bayer AS, et al. (2015). Staphylococcus aureus 
metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a 
daptomycin nonsusceptibility phenotype. [10.1128/aac.00160-15]. Antimicrob. Agents Chemother, 
59(7), 4226–4238, doi:10.1128/aac.00160-15. [PubMed: 25963986] 
Gazdar AF, Zweig MH, Carney DN, Van Steirteghen AC, Baylin SB, & Minna JD (1981). Levels of 
creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res, 41(7), 
2773–2777. [PubMed: 6265067] 
Gebregiworgis T, & Powers R (2012). Application of NMR metabolomics to search for human disease 
biomarkers. Comb Chem High Throughput Screen, 15(8), 595–610. [PubMed: 22480238] 
Gebregiworgis T, Purohit V, Shukla SK, Tadros S, Chaika NV, Abrego J, et al. (2017). Glucose 
Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells. J 
Proteome Res, 16(10), 3536–3546, doi:10.1021/acs.jproteome.7b00246. [PubMed: 28809118] 
Glunde K, Penet MF, Jiang L, Jacobs MA, & Bhujwalla ZM (2015). Choline metabolism-based 
molecular diagnosis of cancer: an update. Expert Rev Mol Diagn, 15(6), 735–747, doi:
10.1586/14737159.2015.1039515. [PubMed: 25921026] 
Hara T, Kosaka N, & Kishi H (1998). PET imaging of prostate cancer using carbon-11-choline. J. 
Nucl. Med, 39(6), 990–995. [PubMed: 9627331] 
Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. (2014). Drug resistance 
in cancer: an overview. Cancers (Basel), 6(3), 1769–1792, doi:10.3390/cancers6031769. [PubMed: 
25198391] 
Ju HQ, Gocho T, Aguilar M, Wu M, Zhuang ZN, Fu J, et al. (2015). Mechanisms of Overcoming 
Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox 
Modulation. Mol Cancer Ther, 14(3), 788–798, doi:10.1158/1535-7163.MCT-14-0420. [PubMed: 
25527634] 
Lu SC (2009). Regulation of glutathione synthesis. Mol Aspects Med, 30(1–2), 42–59, doi:10.1016/
j.mam.2008.05.005. [PubMed: 18601945] 
Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, et al. (2010). Survival prediction for 
pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics, 9(4), 695–704, 
doi:10.1074/mcp.M900234-MCP200. [PubMed: 20061307] 
Rahman M, & Hasan MR (2015). Cancer Metabolism and Drug Resistance. Metabolites, 5(4), 571–
600, doi:10.3390/metabo5040571. [PubMed: 26437434] 
Raykov Z, Grekova SP, Bour G, Lehn JM, Giese NA, Nicolau C, et al. (2014). Myo-inositol 
trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances 
gemcitabine efficacy. Int J Cancer, 134(11), 2572–2582, doi:10.1002/ijc.28597. [PubMed: 
24214898] 
Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, et al. (2017). MUC1 and 
HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine 
Resistance to Pancreatic Cancer. Cancer Cell, 32(1), 71–87 e77, doi:10.1016/j.ccell.2017.06.004. 
[PubMed: 28697344] 
Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, et al. (2016). Pancreatic 
stellate cells support tumour metabolism through autophagic alanine secretion. Nature, 536(7617), 
479–483, doi:10.1038/nature19084. [PubMed: 27509858] 
Tu S, Zhang X, Luo D, Liu Z, Yang X, Wan H, et al. (2015). Effect of taurine on the proliferation and 
apoptosis of human hepatocellular carcinoma HepG2 cells. Exp Ther Med, 10(1), 193–200, doi:
10.3892/etm.2015.2476. [PubMed: 26170934] 
Uhr K, Prager-van der Smissen WJ, Heine AA, Ozturk B, Smid M, Gohlmann HW, et al. (2015). 
Understanding drugs in breast cancer through drug sensitivity screening. Springerplus, 4, 611, doi:
10.1186/s40064-015-1406-8. [PubMed: 26543746] 
Gebregiworgis et al. Page 8





















Vucenik I, & Shamsuddin AM (2003). Cancer inhibition by inositol hexaphosphate (IP6) and inositol: 
from laboratory to clinic. J Nutr, 133(11 Suppl 1), 3778S–3784S. [PubMed: 14608114] 
Worley B, & Powers R (2014). MVAPACK: A Complete Data Handling Package for NMR 
Metabolomics. [10.1021/cb4008937]. ACS Chem. Biol, 9(5), 1138–1144, doi:10.1021/cb4008937. 
[PubMed: 24576144] 
Yang M, & Vousden KH (2016). Serine and one-carbon metabolism in cancer. [10.1038/nrc.2016.81]. 
Nat. Rev. Cancer, 16(10), 650–662, doi:10.1038/nrc.2016.81. [PubMed: 27634448] 
Gebregiworgis et al. Page 9





















Figure 1. Unique metabolic phenotype for gemcitabine resistant cells.
(A) PCA scores plot generated from 1D 1H NMR spectra from cell lysates of wild type 
T3M4 cells (WT,  n=8), WT cells treated with 10 nM of gemcitabine (WT+,  n=9), 
gemcitabine-resistant (GemR,  n=10) cells, and GemR cells treated with 10 nM of 
gemcitabine (GemR+,  n=8). Please see supplemental methods and Figure S-4 for 
explanation of excluded outliers. The ellipses correspond to 95% confidence intervals for a 
normal distribution. (B) Metabolic tree diagram generated from the PCA score plots. The 
number at each node is the p-value calculated from the Mahalanobis distance between each 
group. The coloring is identical to the PCA scores plot. (C) Back-scaled loadings plot 
generated from a validated OPLS-DA model (R2 0.99, Q2 0.90, CV-ANOVA p-value 7.94 × 
10−7, permutation test p-value 0) comparing the WT and WT+ 1D 1H NMR datasets. 
Positive peaks indicate an increase in WT+ and negative peaks are a decrease in WT+. (D) 
Metabolic pathway summarizing the key metabolite differences between WT and WT+ as 
determined from the OPLS-DA back-scaled loadings plot in C. An up arrow indicates an 
increase in the metabolite in WT+ and a down arrow indicates a decrease in the metabolite 
in WT+. (E) Back-scaled loadings plot generated from a validated OPLS-DA model (R2 
0.99, Q2 0.96, CV-ANOVA p-value 2.52 X 10−7, permutation test p-value 0) comparing the 
WT and GemR 1D 1H NMR datasets. Positive peaks indicate an increase in GemR and 
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negative peaks are a decrease in GemR (F) Metabolic pathway summarizing the key 
metabolite differences between WT and GemR as determined from the OPLS-DA back-
scaled loadings plot in E. An up arrow indicates an increase in the metabolite in Gem R and 
a down arrow indicates a decrease in the metabolite in GemR. The metabolite labeling in the 
OPLS-DA back-scaled loadings plots in C and E are numbered as follows: 1, branched 
chain amino acids (leucine, isoleucine, valine); 2, lactate; 3, alanine; 4, acetate; 5, glutamate; 
6, glutamine; 7,glutathione; 8,malate; 9,aspartate; 10, creatinine; 11, creatinine phosphate; 
12, glycerophosphocholine; 13, taurine, 14, glycine, 15, myo-inositol 16, AXP (AMP, ADP, 
and ATP).
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Figure 2. Altered metabolism in gemcitabine resistant cells.
(A) Heatmap and hierarchical clustering analysis generated from 2D 1H-13C HSQC spectra 
of WT, WT+, GemR and GemR+ cell lysates. Peak intensities for each metabolite was 
normalized by the mean of all the peaks and then scaled by the maximum peak intensity for 
the metabolite across the four groups. The column clustering identifies group membership 
and the row clustering identifies metabolites with similar trends across the groups. (B) A 
metabolic pathway summarizing the metabolite differences between WT and GemR (first 
arrow); and between WT and WT+ (second arrow), respectively. A red arrow indicates a 
decrease in the metabolite in WT+ or GemR relative to WT. A green arrow indicates an 
increase in the metabolite in WT+ or GemR relative to WT.
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